Thus, to target paclitaxel anticancer drug to HCC cells, scientists created unique ASGPR-targeting poly (polyethylene glycol paclitaxel) (PTX) nanoliposomes that contain PTX and active ligands which directly strike HCC cells. This evidence concerns the gene ASGR1 and hepatocellular carcinoma.